AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18626783 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal urethrosphincteric block (TUSB) using 10‐20 ml of 1% lidocaine
Number of subjects: 150
Study 18626783 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral 30 ml of 2% lidocaine jelly
Number of subjects: 150
Study 18626783 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral 30 ml of neutral jelly
Number of subjects: 150
Study 17988462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysis with Escherichia coli beta‐glucuronidase followed by 10N NaOH; urine samples adjusted to pH 5-6.5, treated with acetonitrile, and quantified by gas chromatography-mass spectrometry.
Number of subjects: 0
Study 16230677 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with oxaliplatin 70 mg/m2 weekly for six doses
Number of subjects: 115
Study 16230677 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 115
Study 11955392 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 IU/kg/day recombinant human growth hormone (rhGH) from postoperative day 1 to day 10
Number of subjects: 50
Study 11955392 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study 11955392 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 IU/kg/day recombinant human growth hormone (rhGH)
Number of subjects: 50
Study 10507268 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐second inhalations of methacholine
Number of subjects: 10
Study 10507268 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐minute inhalations of methacholine
Number of subjects: 10
Study 10507268 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 2‐minute PC20 multiplied by 4 and 30‐second PC20
Number of subjects: 10
Study 8565538 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/hr rhIL-1ra
Number of subjects: 893
Study 8565538 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg/hr rhIL-1ra
Number of subjects: 893
Study 8565538 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-1ra (both dosages)
Number of subjects: 893
Study 8565538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study 1827013 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 20
Study 1827013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1827013 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 20
Study 6282460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 73
Study 6282460 — intervention group
Group type: EXPERIMENTAL
Intervention: Maytansine
Number of subjects: 73
Study 6282460 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorozotocin
Number of subjects: 73
Study 31102438 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 31
Study 31102438 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 31
Study 31102438 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 31
Study 28948420 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 102
Study 28948420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26264425 — intervention group
Group type: COMPARATOR
Intervention: Strength Training + Placebo (ST + placebo)
Number of subjects: 54
Study 26264425 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training + Testosterone Treatment (ST + TT)
Number of subjects: 54
Study 26264425 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Treatment (TT)
Number of subjects: 54
Study 26264425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24119807 — intervention group
Group type: COMPARATOR
Intervention: Humulin‐N (H)
Number of subjects: 30
Study 24119807 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (L)
Number of subjects: 30
Study 24119807 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 21598491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured resin combined with dentin pin
Number of subjects: 38
Study 21598491 — intervention group
Group type: COMPARATOR
Intervention: Dual-cured resin (control group)
Number of subjects: 38
Study 19411792 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program using problem-based learning, 5 weekly sessions, 100-120 min/session
Number of subjects: 44
Study 19411792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education program)
Number of subjects: 44
Study 18060072 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal formulations of UK-39 (10 microg dose)
Number of subjects: 46
Study 18060072 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of UK-39 and AMA49-C1 loaded virosomes
Number of subjects: 46
Study 18060072 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified total IgG from UK-39 immunized volunteers
Number of subjects: 46
Study 18060072 — intervention group
Group type: COMPARATOR
Intervention: Empty virosomes
Number of subjects: 46
Study 15606400 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-oesophageal reflux disease subjects
Number of subjects: 83
Study 15606400 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 83
Study 11023168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5 microg/kg/min, increased every 20 min by 2.5 microg/kg/min up to 10 microg/kg/min)
Number of subjects: 66
Study 11023168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg/min, increased every 20 min by 2.5 microg/kg/min up to 10 microg/kg/min)
Number of subjects: 66
Study 11023168 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from dobutamine to dopamine
Number of subjects: 66
Study 11023168 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from dopamine to dobutamine
Number of subjects: 66
Study 9059563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (150 mg/day) for 3 years
Number of subjects: 22
Study 9059563 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of pamidronate therapy for 12 months
Number of subjects: 22
Study 9059563 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discontinuation BMD measurement after 1 year
Number of subjects: 22
Study 1347659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 8
Study 1347659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg
Number of subjects: 8
Study 1347659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg
Number of subjects: 8
Study 1347659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4054700 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (500 mg)
Number of subjects: 2
Study 4054700 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (100 mg) plus carbidopa (35 mg) after pretreatment with carbidopa (50 mg every six hours for four doses)
Number of subjects: 2
Study 4054700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3678161 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine/Sodium Ioxaglate (Hexabrix 320)
Number of subjects: 94
Study 3678161 — intervention group
Group type: COMPARATOR
Intervention: Meglumine/Sodium Diatrizoate (Urografin 310)
Number of subjects: 94
Study 31721153 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 399
Study 31721153 — intervention group
Group type: COMPARATOR
Intervention: PORT
Number of subjects: 399
Study 30537937 — intervention group
Group type: EXPERIMENTAL
Intervention: BEATVIC therapy (body-oriented resilience therapy using kickboxing exercises)
Number of subjects: 24
Study 25742631 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure (<15 psi)
Number of subjects: 9
Study 25742631 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure (>20 psi)
Number of subjects: 9
Study 23065684 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Ovarian Cancer Algorithm (ROCA)
Number of subjects: 251
Study 20039959 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 211
Study 20039959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 18398147 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (80 mg/d)
Number of subjects: 1389
Study 18398147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1389
Study 16608025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-chewing (three times a day after operation)
Number of subjects: 22
Study 16608025 — intervention group
Group type: COMPARATOR
Intervention: Control (no gum-chewing)
Number of subjects: 22
Study 15071266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing with rate drop sensing
Number of subjects: 100
Study 15071266 — intervention group
Group type: COMPARATOR
Intervention: Sensing without pacing (Control)
Number of subjects: 100
Study 15071266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing (overall)
Number of subjects: 100
Study 11082523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral resin-bonded bridges
Number of subjects: 40
Study 11082523 — intervention group
Group type: COMPARATOR
Intervention: Lower partial denture
Number of subjects: 40
Study 11082523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic rehabilitation (both interventions)
Number of subjects: 40
Study 9384340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc-D (tetravalent pneumococcal vaccine conjugated to diphtheria toxoid)
Number of subjects: 75
Study 9384340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc-T (tetravalent pneumococcal vaccine conjugated to tetanus toxoid)
Number of subjects: 75
Study 9384340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1543819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg am
Number of subjects: 264
Study 1543819 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg nocte
Number of subjects: 264
Study 3159324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass closure (all layers except skin)
Number of subjects: 282
Study 3159324 — intervention group
Group type: COMPARATOR
Intervention: Layered closure (anterior and posterior aponeuroses separately sutured)
Number of subjects: 282
Study 30657251 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial tubular superelastic NiTi
Number of subjects: 40
Study 30657251 — intervention group
Group type: COMPARATOR
Intervention: Single-stranded superelastic NiTi
Number of subjects: 40
Study 29763709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 422
Study 29763709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 27028957 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analog (SSA) therapy
Number of subjects: 36
Study 27028957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SSA therapy)
Number of subjects: 36
Study 23640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy regimen
Number of subjects: 134
Study 23640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of UAI
Number of subjects: 134
Study 23640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic factors (Latino ethnicity)
Number of subjects: 134
Study 23640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (crystal methamphetamine use, greater life stress, lower trait anxiety)
Number of subjects: 134
Study 23640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem drinking
Number of subjects: 134
Study 23681906 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dual release ciprofloxacin (DRCFI)
Number of subjects: 42
Study 23681906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20492710 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold+Lutein (Wyeth S‐26 Gold fortified with lutein at 200 mcg/l)
Number of subjects: 232
Study 20492710 — intervention group
Group type: COMPARATOR
Intervention: Gold (Wyeth S‐26 Gold, control formula)
Number of subjects: 232
Study 20492710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 232
Study 19102266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support increased intravenously for 14 days (7 days before and after operation)
Number of subjects: 48
Study 19102266 — intervention group
Group type: COMPARATOR
Intervention: Routine diet (Control group)
Number of subjects: 48
Study 17277679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 286
Study 17277679 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 286
Study 12580941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 IU GH
Number of subjects: 26
Study 12580941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 IU GH
Number of subjects: 26
Study 12580941 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 IU GH
Number of subjects: 26
Study 12580941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IU GH
Number of subjects: 26
Study 10849523 — intervention group
Group type: EXPERIMENTAL
Intervention: Roquinimex 0.2 mg/kg body weight, twice weekly for 2 years
Number of subjects: 278
Study 10849523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 9203426 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose amphotericin B (0.7 mg/kg/day) plus flucytosine (100 mg/kg/day) for two weeks
Number of subjects: 202
Study 9203426 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose amphotericin B (0.7 mg/kg/day) alone
Number of subjects: 202
Study 9203426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day) for eight weeks
Number of subjects: 202
Study 9203426 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg/day) for eight weeks
Number of subjects: 202
Study 9203426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day)
Number of subjects: 202
Study 9203426 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg/day)
Number of subjects: 202
Study 9203426 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 202
Study 1313104 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrice (standard abrasivity)
Number of subjects: 40
Study 1313104 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrice (low abrasivity)
Number of subjects: 40
Study 1313104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 3697596 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC prone (tank) method
Number of subjects: 80
Study 3697596 — intervention group
Group type: COMPARATOR
Intervention: RV seated (pool) method
Number of subjects: 80
Study 31339000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF) from 8 am to 2 pm
Number of subjects: 11
Study 31339000 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF)
Number of subjects: 11
Study 31339000 — intervention group
Group type: COMPARATOR
Intervention: Control schedule (eating from 8 am to 8 pm)
Number of subjects: 11
Study 29402752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d for 3 years or until recurrence)
Number of subjects: 264
Study 29402752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 26322788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vets Prevail online cognitive-behavioral therapy intervention
Number of subjects: 303
Study 26322788 — intervention group
Group type: COMPARATOR
Intervention: Adjustment as usual (control)
Number of subjects: 303
Study 25704335 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative intervention to support unmarried coparents
Number of subjects: 0
Study 25704335 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23489232 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine and 1,450 ppm sodium monofluorophosphate dentifrice
Number of subjects: 85
Study 23489232 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium acetate and 1,040 ppm sodium fluoride dentifrice
Number of subjects: 85
Study 23489232 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% microaggregation of zinc‐carbonate hydroxyapatite nanocrystals dentifrice
Number of subjects: 85
Study 20845628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg-1 intravenously 20 min before completion of surgery
Number of subjects: 76
Study 20845628 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 76
Study 19014842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren (8-12 mg/kg daily) for 14 days
Number of subjects: 142
Study 19014842 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (80-90 mg/kg amoxicillin daily) for 14 days
Number of subjects: 142
Study 19014842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren
Number of subjects: 142
Study 19014842 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 142
Study 16152828 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Tongli (JPTL) Chinese herbs
Number of subjects: 60
Study 16152828 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 60
Study 12855319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg q.i.d.
Number of subjects: 115
Study 12855319 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 10 mg q.i.d.
Number of subjects: 115
Study 12855319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 115
Study 10100579 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1 g twice daily for 12 months
Number of subjects: 69
Study 10100579 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1 g twice daily for 12 months plus intranasal calcitonin 400 IU/day for the first month and then 200 IU/day for 11 months
Number of subjects: 69
Study 10100579 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 69
Study 8946451 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR mode (minute ventilation sensing)
Number of subjects: 10
Study 8946451 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR mode (activity sensing)
Number of subjects: 10
Study 8946451 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR mode (dual sensor)
Number of subjects: 10
Study 8946451 — intervention group
Group type: COMPARATOR
Intervention: VVI mode (no rate response)
Number of subjects: 10
Study 8946451 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR modes (all types)
Number of subjects: 10
Study 8946451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sensor pacing
Number of subjects: 10
Study 8946451 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity sensing VVIR mode
Number of subjects: 10
Study 1835301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel, 0.5 mg
Number of subjects: 100
Study 1835301 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100
Study 1835301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (meta-analysis)
Number of subjects: 100
Study 6109801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrone sulphate
Number of subjects: 60
Study 6109801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30942898 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1773
Study 30942898 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1773
Study 30942898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study 30942898 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (both doses)
Number of subjects: 1773
Study 27776382 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone-on-release (NOR)
Number of subjects: 1685
Study 27776382 — intervention group
Group type: COMPARATOR
Intervention: Control (no syringe)
Number of subjects: 1685
Study 25363203 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG + L (Connective Tissue Graft with Low-Level Laser Therapy)
Number of subjects: 40
Study 25363203 — intervention group
Group type: COMPARATOR
Intervention: CTG (Connective Tissue Graft)
Number of subjects: 40
Study 25363203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CTG and CTG + L)
Number of subjects: 40
Study 23458226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg tablet under fed conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg tablet under fed conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg tablet under fed conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 5 mg tablet
Number of subjects: 24
Study 23458226 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 10 mg tablet under fasting conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg tablet under fasting conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg tablet under fasting conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 10 mg oral suspension under fasting conditions
Number of subjects: 24
Study 23458226 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg oral suspension under fasting and fed conditions
Number of subjects: 24
Study 22136014 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 57
Study 22136014 — intervention group
Group type: COMPARATOR
Intervention: Seretide
Number of subjects: 57
Study 22136014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57